Internal Medicine, Nephrology · Flushing, NY
NPI
1144394966
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
164-10 Northern Blvd, Suite 210
Flushing, NY, 11358
Phone (718) 321-8333
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
388 services
Medicare patients, 2024
69
Average age 76
Drug cost, 2024
$3.0M
15,604 prescriptions
Company payments, 2025
$1,333
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Edward E Lee was code 99213 (office e&m - established), 112 times for 46 patients. In total Edward E Lee billed 388 services in 10 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-06-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 112 | 46 | $72.36 | $8,105 |
| 99214 Office E&M - Established | Office | 78 | 47 | $91.86 | $7,165 |
| 96372 Injection Administration | Office | 61 | 22 | $10.57 | $645 |
| 36415 Venipuncture Blood Collection | Office | 30 | 20 | $8.65 | $260 |
| 81000 Clinical Chemistry | Office | 28 | 26 | $3.94 | $110 |
| 93000 Electrocardiogram | Office | 26 | 25 | $10.47 | $272 |
By year: 2022 $72K for 1,023 services; 2023 $53K for 831 services; 2024 $24K for 388 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 30 | 20 | $8.65 | $260 |
| 81000 Clinical Chemistry | 28 | 26 | $3.94 | $110 |
Medicare prescription drug claims, 2024
In 2024, the drug Edward E Lee prescribed most often to Medicare patients was Atorvastatin Calcium, with 1,116 prescriptions and refills. In total Edward E Lee wrote 15,604 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 1,116 | 1,720 | 183 | $4,287 |
| Amlodipine Besylate Generic | 923 | 1,271 | 143 | $2,888 |
| Vascepa Icosapent Ethyl | 780 | 895 | 105 | $314K |
| Metoprolol Succinate Generic | 678 | 947 | 114 | $3,590 |
| Losartan Potassium Generic | 662 | 933 | 110 | $2,045 |
| Levothyroxine Sodium Generic | 518 | 657 | 82 | $2,512 |
| Metformin Hcl Generic | 432 | 637 | 71 | $1,426 |
| Mirtazapine Generic | 387 | 403 | 53 | $4,402 |
| Tamsulosin Hcl Generic | 387 | 561 | 68 | $1,538 |
| Doxazosin Mesylate Generic | 370 | 474 | 63 | $1,843 |
| Repaglinide Generic | 360 | 476 | 51 | $4,918 |
| Creon Lipase/Protease/Amylase | 283 | 311 | 50 | $309K |
| Omeprazole Generic | 279 | 329 | 54 | $1,982 |
| Simvastatin Generic | 277 | 378 | 46 | $919 |
| Tradjenta Linagliptin | 277 | 355 | 38 | $181K |
Brand drugs: 4,039 claims; generic drugs: 11,245 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Edward E Lee $1,333 ($1,333 in general payments such as food, travel and fees) from 13 companies. The largest payer was Bayer Healthcare Pharmaceuticals Inc. with $260.
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 16 | $260 |
| OPKO Pharmaceuticals, LLC | 10 | $191 |
| Amgen Inc. AMGN | 3 | $174 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $140 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 5 | $100 |
| Travere Therapeutics, Inc. TVTX | 4 | $97.74 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $77.58 |
| Sumitomo Pharma America, Inc. 4506.T | 3 | $71.97 |
| Abbvie Inc. ABBV | 3 | $55.58 |
| Gilead Sciences, Inc. GILD | 2 | $53.22 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.